Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18259772 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL671775 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL28233832 | 0.76 | AKR1B1 (0.36) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL198041 | 0.76 | AKR1B1 (0.36) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL23856035 | 0.73 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL112933 | 0.73 | AKR1B1 (0.39) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL5496629 | 0.73 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL18383123 | 0.73 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL2453623 | 0.73 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL28647875 | 0.73 | AKR1B1 (0.39) | AKR1B1LMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465913-A4 | HETEROCONFIGURATIONAL POLYNUCLEOTIDE AND METHODS OF USE | APPLERA CORP (US) | 2008-02-13 | — | — | EP | claimed |
| US-20060286581-A1 | Heteroconfigurational Polynucleotides and Methods of Use | APPLERA CORPORATION; APPLIED BIOSYSTEMS GROUP (US) | 2006-12-21 | — | — | US | claimed |
| EP-1465913-A1 | HETEROCONFIGURATIONAL POLYNUCLEOTIDE AND METHODS OF USE | Applera Corporation (US) | 2004-10-13 | — | — | EP | claimed |
| US-20030198980-A1 | Comprising a D-form polynucleotide sequence portion and an L-form polynucleotide sequence portion that are covalently linked | APPLERA CORPORATION | 2003-10-23 | — | — | US | claimed |
| WO-2003059929-A1 | HETEROCONFIGURATIONAL POLYNUCLEOTIDE AND METHODS OF USE | APPLERA CORPORATION (US) | 2003-07-24 | — | — | WO | claimed |
| US-11993791-B2 | Modification of 3′ terminal ends of nucleic acids by DNA polymerase theta | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024104914-A1 | RNA CAPPING EFFICIENCY ASSAY | BioNTech SE (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-11987796-B2 | Interferon production using short RNA duplexes | YALE UNIVERSITY (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240115596-A1 | COMPOSITIONS AND METHODS FOR TREATING SARS-COV-2 INFECTION | UNIV YALE (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4347875-A1 | ASSAY FOR QUANTITATIVE ASSESSMENT OF MRNA CAPPING EFFICIENCY | Translate Bio, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240092821-A1 | SYNTHESIS OF OLIGONUCLEOTIDES AND RELATED COMPOUNDS | Janssen Biopharma, Inc. | 2024-03-21 | — | — | US | disclosed |
| CN-117677710-A | Assays for quantitative assessment of mRNA capping efficiency | 翻译生物公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2003045310-A2 | DIGITAL ASSAY | APPLERA CORPORATION (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003040395-A2 | UNIVERSAL NUCLEOTIDES FOR NUCLEIC ACID ANALYSIS | APPLERA CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
| US-20030082547-A1 | Non-fluorescent quencher compounds and biomolecular assays | APPLIED BIOSYSTEMS, LLC | 2003-05-01 | — | — | US | disclosed |
| WO-2003019145-A2 | NON-FLUORESCENT QUENCHER COMPOUNDS AND BIOMOLECULAR ASSAYS | APPLERA CORPORATION (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20030013089-A1 | Dye-labeled ribonucleotide triphosphates | APPLIED BIOSYSTEMS, LLC | 2003-01-16 | — | — | US | disclosed |
| WO-2003000841-A2 | DYE-LABELED RIBONUCLEOTIDE TRIPHOSPHATES | APPLERA CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002072864-A2 | REAGENTS FOR OLIGONUCLEOTIDE CLEAVAGE AND DEPROTECTION | APPLERA CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2001094638-A2 | ASYNCHRONOUS PRIMED PCR | APPLERA CORPORATION (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030198980-A1 | Comprising a D-form polynucleotide sequence portion and an L-form polynucleotide sequence portion that are covalently linked | POLL, DPYD, POLN | AKR1B1 2520/4885LMNA 53/4885L3MBTL1 257/4885 |
| US-20240115596-A1 | COMPOSITIONS AND METHODS FOR TREATING SARS-COV-2 INFECTION | EIF2AK2, MAVS, SARS1 | AKR1B1 3794/4885LMNA 1661/4885L3MBTL1 164/4885 |
| US-20030082547-A1 | Non-fluorescent quencher compounds and biomolecular assays | DNTT, PNP, NT5C2 | AKR1B1 3600/4885LMNA 557/4885L3MBTL1 866/4885 |
| US-20030013089-A1 | Dye-labeled ribonucleotide triphosphates | DUT, POLRMT, SAMHD1 | AKR1B1 341/4885LMNA 1985/4885L3MBTL1 1283/4885 |
| US-11987796-B2 | Interferon production using short RNA duplexes | EIF2AK2, IFNAR1, IFNG | AKR1B1 3449/4885LMNA 3670/4885L3MBTL1 1840/4885 |
| US-20060286581-A1 | Heteroconfigurational Polynucleotides and Methods of Use | NUDT1, DPYD, POLN | AKR1B1 2788/4885LMNA 362/4885L3MBTL1 573/4885 |
| US-20240092821-A1 | SYNTHESIS OF OLIGONUCLEOTIDES AND RELATED COMPOUNDS | RNGTT, DCLRE1B, ADAR | AKR1B1 3041/4885LMNA 2463/4885L3MBTL1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.